awmsg logo



riociguat (Adempas®)


Reference No. 1608

Publication date:
13/10/2015


Appraisal information

riociguat (Adempas®) 0.5 mg film-coated tablet
riociguat (Adempas®) 1 mg film-coated tablet
riociguat (Adempas®) 1.5 mg film-coated tablet
riociguat (Adempas®) 2 mg film-coated tablet
riociguat (Adempas®) 2.5 mg film-coated tablet


Company: Bayer Healthcare Pharmaceuticals
BNF category: Cardiovascular system
NMG meeting date: 22/07/2015
AWMSG meeting date: 16/09/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2415
Ministerial ratification: 09/10/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Riociguat (Adempas®) is recommended for use within NHS Wales for the treatment of adult patients with WHO functional class II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH); or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download